QuidelOrtho (QDEL) Q3 2026 Earnings Call Transcript

QuidelOrtho reported Q3 2026 revenue of $619M, down 12% YoY, with declines in Point of Care and China sales. Excluding China and respiratory, revenue rose 3%. The company announced a restructuring program to save $80M annually in 2027, focusing on cost cuts and business realignment. Management emphasized long-term growth strategies, including expanding the VITROS 450 and NULEXA platforms.

Original reporting
Published Nov 4, 2026, 4:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 5:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
QuidelOrtho (QDEL) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$QDELBearishMed
01

Why it matters

The call combines a quantified earnings snapshot (Q3 revenue down 12% YoY) with forward-looking operational guidance (continued China destocking through 2026, increased pricing pressure in 2027) and a quantified cost program (>$80M annual savings in 2027, $30M-$35M restructuring charges in 4Q26).

02

Market read

Traders can update estimates for margins and free cash flow using the disclosed restructuring savings and charges, while also pricing ongoing China and respiratory demand headwinds into 2026-2027.

03

What to watch

Provincial implementation timing uncertainty in China could extend volatility; also, the magnitude and cash timing of restructuring charges ($30M-$35M, mostly in 4Q26) can pressure near-term free cash flow despite longer-term savings.

Relevance 8/10Novelty 7/10Timing: during/after the Q3 earnings call, with restructuring charges and 2027 savings guidance disclosed

Background

QuidelOrtho is restructuring its operating model into two focused businesses, core diagnostics and point-of-care diagnostics, while winding down U.S. donor screening and navigating China IVD pricing guideline changes.

Company-level read

Ticker impact

$QDELBearishHigh confidence
Context

QuidelOrtho reports Q3 revenue down 12% YoY and guides continued China destocking, while announcing a cost transformation targeting $80M+ annual savings in 2027.

Expected impact

Likely mixed reaction, with downside risk from China/respiratory softness offset by upside from quantified restructuring savings and restructuring charges.

Evidence & confidence

The transcript includes specific Q3 revenue declines, China destocking and 2027 pricing pressure, plus quantified restructuring savings and restructuring charge timing, which are direct inputs to near-term estimates and longer-term margin/cash-flow models.

Market effects

Diagnostic and point-of-care peers may face read-through on China IVD pricing guideline impacts and margin pressure versus cost actions.

China revenue decline and distributor destocking expectations highlight ongoing demand softness and pricing pressure into 2027.

Outside China, labs and immunohematology growth suggests resilience that could influence sentiment toward global in-vitro diagnostics demand.

Counterpoint

The $80M+ 2027 savings may not fully offset near-term revenue declines if China destocking and 2027 pricing pressure persist longer than management’s assumptions.

Key entities

  • QuidelOrtho

    Subject of the earnings call transcript, reporting Q3 results and announcing a cost transformation and enterprise restructuring program.

  • China nationwide IVD pricing guidelines

    Policy change driving distributor and customer destocking, with provincial implementation timing uncertain.

  • NULEXA

    Point-of-care molecular platform discussed as early in launch with menu expansion opportunities.

  • VITROS 450

    Labs analyzer launch expansion to additional international markets mentioned as part of innovation investment.

Related articles

$QDELHighAI 8/10

QuidelOrtho Corp (QDEL) Q3 2026 Earnings Call Highlights: Revenue Falls 12% on China

QuidelOrtho Corp (QDEL) reported a 12% year-over-year revenue decline to $619 million in Q3 2026, driven by China destocking and softer respiratory testing. China revenue dropped 45% due to pricing changes and destocking, with further pressure expected. Adjusted gross margin contracted to 47.8%, and net leverage increased to 4.5 times EBITDA. The company plans cost savings and structural changes to offset headwinds and improve profitability.

$QDELMedAI 8/10

What QuidelOrtho (QDEL) Said on Its Q3 Earnings Call

QuidelOrtho (QDEL) reported Q3 revenue decline, with Point of Care down 27% YoY. Management maintained a cautious outlook. The company announced a restructuring program targeting $80M in annual savings by 2027, with $30M-$35M in one-time charges in Q4. Adjusted EBITDA was $148M, and adjusted EPS was $0.31. QDEL narrowed its full-year revenue outlook to $2.52B-$2.54B and adjusted EBITDA to $540M-$545M.

$QDELHighAI 8/10

QuidelOrtho Q3 2026 slides: profit beat masks revenue challenges

QuidelOrtho (QDEL) reported Q3 2026 earnings of $0.31 per share, beating estimates, but revenue of $618.9M missed forecasts, causing a 6.62% after-hours drop. Revenue declined 12% YoY due to China's IVD pricing guidelines, with North America down 13.3% and China down 45.5%. Management narrowed full-year guidance, citing continued China pressure and cautious respiratory demand outlook. The company announced a restructuring plan to save $80M annually from 2027.

$QDELHighAI 8/10

QuidelOrtho: Q3 Earnings Snapshot

QuidelOrtho (QDEL) reported a Q3 loss of $53.8M, or 78 cents per share, with adjusted earnings of 31 cents per share. Revenue was $618.9M. The company expects full-year earnings of 65-70 cents per share and revenue of $2.52B-$2.54B, according to its Tuesday report.